An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy

Acar N. P., Tuncer A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., ...Daha Fazla

JOURNAL OF NEUROIMMUNOLOGY, cilt.347, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 347
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.jneuroim.2020.577353
  • Dergi Adı: JOURNAL OF NEUROIMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Anahtar Kelimeler: Fingolimod, Interferon, Next-generation sequencing, NKp46, Immunomodulation, Multiple sclerosis, NK cells, NATURAL-KILLER-CELLS, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, PERIPHERAL-BLOOD, FTY720, SUBSETS, MECHANISMS
  • Hacettepe Üniversitesi Adresli: Evet

Özet

This study aims to compare NK cells obtained from multiple sclerosis (MS) patients receiving interferon-beta 1 and fingolimod therapies. Fingolimod reduced the CD56(bright) NK cell subset. The remaining CD56(dim) NK cells displayed NKG2D, NKp46, CD107a, and IFN-gamma levels similar to those from the patients under interferon-beta 1 therapy. Alternatively, comparative transcriptomics and pathway analyses revealed significant distinctions between two therapy modalities. Molecular signature of the CD56(dim) NK cells from fingolimod-treated MS patients was closely associated to those from healthy subjects. The basic assets of NK cells were modestly influenced by interferon-beta 1 and fingolimod, however transcriptomics showed profound alterations in NK responses.